Our Commitment to Oncology
Ipsen’s oncology franchise is key to the success of our business. Our strategy is to be a leader in treating solid and blood tumors in patient populations with high unmet medical needs.
Working with and for patients guides our strategy. Patients and their families inspire and drive us to tackle some of the hardest-to-treat cancers where we can have a direct impact for those who need treatment the most. That’s why we actively listen to and learn from their experiences, integrating their insights into our efforts, from early research through development.
We also work closely with patient groups to understand the factors that play a role in improving a patient’s quality of life. Through these collaborations we look to co-create solutions that effectively support patients.
By focusing on selected cancers and working with like-minded partners, we are fostering solutions, advancing science and delivering new, innovative treatments with the patient at the center of everything we do.
Ipsen entered the field of oncology in 1986, and today we have a portfolio including treatments for neuroendocrine tumors (NETs), and cancers of the kidney, liver, pancreas, thyroid, prostate and breast.
75% of Ipsen’s global sales are in oncology, making us one of the top global oncology companies.
In the U.S., we are bringing new insights to the treatment of NETs by applying Artificial Intelligence to our clinical trial data. Our investment in advanced analytics allows us to build predictive models to deliver better patient outcomes.
Our Areas of Expertise
Our oncology expertise focuses on solid and blood tumors with high unmet medical needs in patient populations that are currently not well supported.
Our Oncology Pipeline
At Ipsen, we believe that great partnerships create great possibilities. A culture of external innovation drives our research, development and commercialization. We identify, develop and integrate innovative products that are a strategic fit for our portfolio and that deliver value for patients. With like-minded partners, our goal is to foster solutions, advance science and deliver new therapies.
Ipsen has built its strength in oncology through solid long-term partnerships which are fast-tracking new approaches to target hard-to-treat cancers that are often overlooked as research targets.
Over the next few years, we will continue to build our high value and sustainable pipeline. We are seeking collaborations with companies who are advancing approved products, investigational assets or a novel preclinical approach in both solid tumors and blood cancers, including niche tumors and broader populations with a biomarker segmentation.
Learn more about our pipelineWorking with Patients and Healthcare Providers
Ipsen’s priority is to improve the lives of patients, their caregivers, their communities and, ultimately, society. We seek opportunities to go further and reach more patients, advocacy groups and healthcare providers because every patient is unique and requires their own support system. We have built strong, long-term partnerships with patient associations and healthcare providers, and we frequently invest in efforts to increase disease awareness and education, including:
Oncology Patient Advocacy Organizations
We collaborate with oncology patient organizations around the world to ensure we are responding to patient needs, understanding their perspectives and raising awareness of difficult-to-treat cancers.
EverydayWins®
The EverydayWins® initiative was developed in collaboration with patient organizations, including Europa Donna, to provide women who are living with breast cancer with disease information and resources.
Perspectives Matter in Kidney Cancer
Perspectives Matter, in collaboration with patient organizations, aims to shine a light on the feelings, experiences and perspectives of people who have direct experience of kidney cancer – through a series of bespoke illustrations.
Partnering
We believe that great partnerships create great possibilities. We are on a mission to deliver at least one new molecular entity or meaningful indication each year and collaborations with other like-minded innovators are key for the next phase of our growth.
Investors
Visit our dedicated investor section to find more information on financial results, our financial calendar and more.